344 related articles for article (PubMed ID: 35053194)
41. Practical experience using galectin-3 in heart failure.
McCullough PA
Clin Chem Lab Med; 2014 Oct; 52(10):1425-31. PubMed ID: 24810562
[TBL] [Abstract][Full Text] [Related]
42. Prognostic Value of Serial Measurements of Soluble Suppression of Tumorigenicity 2 and Galectin-3 in Ambulatory Patients With Chronic Heart Failure.
Miller WL; Saenger AK; Grill DE; Slusser JP; Bayes-Genis A; Jaffe AS
J Card Fail; 2016 Apr; 22(4):249-55. PubMed ID: 26277907
[TBL] [Abstract][Full Text] [Related]
43. Local expression of myocardial galectin-3 does not correlate with its serum levels in patients undergoing heart transplantation.
Beiras-Fernandez A; Weis F; Rothkopf J; Kaczmarek I; Ledderose C; Dick A; Keller T; Beiras A; Kreth S
Ann Transplant; 2013 Nov; 18():643-50. PubMed ID: 24264380
[TBL] [Abstract][Full Text] [Related]
44. Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study.
Lok DJ; Van Der Meer P; de la Porte PW; Lipsic E; Van Wijngaarden J; Hillege HL; van Veldhuisen DJ
Clin Res Cardiol; 2010 May; 99(5):323-8. PubMed ID: 20130888
[TBL] [Abstract][Full Text] [Related]
45. The ARCHITECT galectin-3 assay: comparison with other automated and manual assays for the measurement of circulating galectin-3 levels in heart failure.
Meijers WC; van der Velde AR; de Boer RA
Expert Rev Mol Diagn; 2014 Apr; 14(3):257-66. PubMed ID: 24606321
[TBL] [Abstract][Full Text] [Related]
46. Galectin-3 and Arterial Stiffness in Patients with Heart Failure: A Pilot Study.
Oikonomou E; Karlis D; Tsalamadris S; Siasos G; Chrysohoou C; Vogiatzi G; Dimitropoulos S; Charalambous G; Kouskouni E; Tousoulis D
Curr Vasc Pharmacol; 2019; 17(4):396-400. PubMed ID: 29968538
[TBL] [Abstract][Full Text] [Related]
47. Galectin-3 and the development of heart failure after acute coronary syndrome: pilot experience from PROVE IT-TIMI 22.
Grandin EW; Jarolim P; Murphy SA; Ritterova L; Cannon CP; Braunwald E; Morrow DA
Clin Chem; 2012 Jan; 58(1):267-73. PubMed ID: 22110019
[TBL] [Abstract][Full Text] [Related]
48. Galectin-3 and cardiac function in survivors of acute myocardial infarction.
Weir RA; Petrie CJ; Murphy CA; Clements S; Steedman T; Miller AM; McInnes IB; Squire IB; Ng LL; Dargie HJ; McMurray JJ
Circ Heart Fail; 2013 May; 6(3):492-8. PubMed ID: 23505301
[TBL] [Abstract][Full Text] [Related]
49. Prognostic Value of Galectin-3 for Adverse Outcomes in Chronic Heart Failure.
French B; Wang L; Ky B; Brandimarto J; Basuray A; Fang JC; Sweitzer NK; Cappola TP
J Card Fail; 2016 Apr; 22(4):256-62. PubMed ID: 26571149
[TBL] [Abstract][Full Text] [Related]
50. Galectin-3 in Atrial Fibrillation: Mechanisms and Therapeutic Implications.
Clementy N; Piver E; Bisson A; Andre C; Bernard A; Pierre B; Fauchier L; Babuty D
Int J Mol Sci; 2018 Mar; 19(4):. PubMed ID: 29587379
[TBL] [Abstract][Full Text] [Related]
51. Biomarkers in heart failure: the past, current and future.
Sarhene M; Wang Y; Wei J; Huang Y; Li M; Li L; Acheampong E; Zhengcan Z; Xiaoyan Q; Yunsheng X; Jingyuan M; Xiumei G; Guanwei F
Heart Fail Rev; 2019 Nov; 24(6):867-903. PubMed ID: 31183637
[TBL] [Abstract][Full Text] [Related]
52. Acute cardiac dyspnea in the emergency department: diagnostic value of N-terminal prohormone of brain natriuretic peptide and galectin-3.
Stoica A; Şorodoc V; Lionte C; Jaba IM; Costache I; Anisie E; Tuchiluș C; Rusalim Petriș O; Sîrbu O; Jaba E; Ceasovschih A; Vâţă L; Şorodoc L
J Int Med Res; 2019 Jan; 47(1):159-172. PubMed ID: 30222016
[TBL] [Abstract][Full Text] [Related]
53. Galectin-3 in patients with chronic heart failure: association with oxidative stress, inflammation, renal dysfunction and prognosis.
Medvedeva EA; Berezin II; Surkova EA; Yaranov DM; Shchukin YV
Minerva Cardioangiol; 2016 Dec; 64(6):595-602. PubMed ID: 27119370
[TBL] [Abstract][Full Text] [Related]
54. Using the galectin-3 test to predict mortality in heart failure patients: a systematic review and meta-analysis.
Chen YS; Gi WT; Liao TY; Lee MT; Lee SH; Hsu WT; Chang SS; Lee CC
Biomark Med; 2016; 10(3):329-42. PubMed ID: 26860036
[TBL] [Abstract][Full Text] [Related]
55. Association of the biomarkers soluble ST2, galectin-3 and growth-differentiation factor-15 with heart failure and other non-cardiac diseases.
Mueller T; Leitner I; Egger M; Haltmayer M; Dieplinger B
Clin Chim Acta; 2015 May; 445():155-60. PubMed ID: 25850080
[TBL] [Abstract][Full Text] [Related]
56. Myocardial Galectin-3 Expression Is Associated with Remodeling of the Pressure-Overloaded Heart and May Delay the Hypertrophic Response without Affecting Survival, Dysfunction, and Cardiac Fibrosis.
Frunza O; Russo I; Saxena A; Shinde AV; Humeres C; Hanif W; Rai V; Su Y; Frangogiannis NG
Am J Pathol; 2016 May; 186(5):1114-27. PubMed ID: 26948424
[TBL] [Abstract][Full Text] [Related]
57. A pilot study to demonstrate diagnostic potential of galectin-3 levels in saliva.
Zhang X; Wan Y; Chata R; Brazzale A; Atherton JJ; Kostner K; Dimeski G; Punyadeera C
J Clin Pathol; 2016 Dec; 69(12):1100-1104. PubMed ID: 27340130
[TBL] [Abstract][Full Text] [Related]
58. The emerging role of galectins in cardiovascular disease.
van der Hoeven NW; Hollander MR; Yıldırım C; Jansen MF; Teunissen PF; Horrevoets AJ; van der Pouw Kraan TC; van Royen N
Vascul Pharmacol; 2016 Jun; 81():31-41. PubMed ID: 26945624
[TBL] [Abstract][Full Text] [Related]
59. Mechanisms responsible for increased circulating levels of galectin-3 in cardiomyopathy and heart failure.
Nguyen MN; Su Y; Vizi D; Fang L; Ellims AH; Zhao WB; Kiriazis H; Gao XM; Sadoshima J; Taylor AJ; McMullen JR; Dart AM; Kaye DM; Du XJ
Sci Rep; 2018 May; 8(1):8213. PubMed ID: 29844319
[TBL] [Abstract][Full Text] [Related]
60. The predictive value of plasma biomarkers in discharged heart failure patients: role of galectin-3.
Leone M; Iacoviello M
Minerva Cardioangiol; 2016 Apr; 64(2):181-94. PubMed ID: 26426300
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
